2025 Q4 -tulosraportti
66 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,86%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 623 | - | - | ||
| 42 | - | - | ||
| 8 695 | - | - | ||
| 2 483 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·12 t sitten · MuokattuOn 4 February, Danske bank lowered Novo's price target, from 440 to 390 kr. https://www.sydinvest.dk/nyheder/novo-danske-bank-saenker-kursmaal-til-390-kr-fra-440-kr I read 1-2 weeks ago that if DB's price target for Novo were to hold, Novo would need 210,000 weekly prescriptions for the Wegovy pill by the end of the year. My calculation approx. 4,000 per week on average, or 52,000 in week 13, where we were at 77,903. (The last figures we have received) Novo is on its way to raising the lower end of the announced results. UBS price target 332 kr. https://www.nordnet.dk/markedet/nyheder/8dca6395-e9f1-4e52-b677-de3c93956e19 Novo has previously been a "safe haven", but has taken a lot of beating over the last 1.5 years due to disappointing results, so even though there have been several good news recently, it has not risen on them. Most recently yesterday, that Novo can transport their product under more lenient requirements (temperatures in number of hours). When we soon see Eli Lilly's sales figures, we must remember that when Novo entered the market with their pill, it was new. Now this new pill product has been "discussed" for and against for 3 months, before Eli Lilly entered the market, so it might mean that they start with higher sales figures than Novo did. But it will be exciting to follow their figures, versus Novo's. I still believe in Novo and on 6 May, when the figures are presented and future expectations/plans are revealed, I believe that they/we will be rewarded in the share price. Management often gets criticized for this and that, and it's easy to sit and write that they are incompetent and should be replaced. People are frustrated that their "safe" investment, which was supposed to make them millionaires in a week, is suddenly in the red. It's certainly not one's own fault, but Novo management!!! Clearly... I am sure that they work extremely hard every single day to deliver results for us and a lot goes on behind the scenes that we have no idea about. But it's so easy to blame others...
18 t sitten18 t sittenInvesting in Novo Feels like having dead money
·19 t sitten · MuokattuRead along here: https://finans.dk/erhverv/ECE19188477/novo-nordisk-sammenlaegger-to-afdelinger-og-foretager-organisatoriske-tilpasninger/https://medwatch.dk/brancher/Medicinal___Biotek/article19191138.ece Updates will certainly follow in the coming days. It is good that NN informs gradually, so fleet possible investors are informed. The news in question began to circulate last week, i.e. the delay is ~1-2 weeks' time in this case, which is fine.
·19 t sittenIs it permissible to hope that we are now beginning, after such a long time, to see that the bottom is near. Such a large company should recover at some point, one would think, but this fall has been heavy, especially for those who have their pensions invested there.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
66 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,86%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·12 t sitten · MuokattuOn 4 February, Danske bank lowered Novo's price target, from 440 to 390 kr. https://www.sydinvest.dk/nyheder/novo-danske-bank-saenker-kursmaal-til-390-kr-fra-440-kr I read 1-2 weeks ago that if DB's price target for Novo were to hold, Novo would need 210,000 weekly prescriptions for the Wegovy pill by the end of the year. My calculation approx. 4,000 per week on average, or 52,000 in week 13, where we were at 77,903. (The last figures we have received) Novo is on its way to raising the lower end of the announced results. UBS price target 332 kr. https://www.nordnet.dk/markedet/nyheder/8dca6395-e9f1-4e52-b677-de3c93956e19 Novo has previously been a "safe haven", but has taken a lot of beating over the last 1.5 years due to disappointing results, so even though there have been several good news recently, it has not risen on them. Most recently yesterday, that Novo can transport their product under more lenient requirements (temperatures in number of hours). When we soon see Eli Lilly's sales figures, we must remember that when Novo entered the market with their pill, it was new. Now this new pill product has been "discussed" for and against for 3 months, before Eli Lilly entered the market, so it might mean that they start with higher sales figures than Novo did. But it will be exciting to follow their figures, versus Novo's. I still believe in Novo and on 6 May, when the figures are presented and future expectations/plans are revealed, I believe that they/we will be rewarded in the share price. Management often gets criticized for this and that, and it's easy to sit and write that they are incompetent and should be replaced. People are frustrated that their "safe" investment, which was supposed to make them millionaires in a week, is suddenly in the red. It's certainly not one's own fault, but Novo management!!! Clearly... I am sure that they work extremely hard every single day to deliver results for us and a lot goes on behind the scenes that we have no idea about. But it's so easy to blame others...
- 18 t sitten18 t sittenInvesting in Novo Feels like having dead money
- ·19 t sitten · MuokattuRead along here: https://finans.dk/erhverv/ECE19188477/novo-nordisk-sammenlaegger-to-afdelinger-og-foretager-organisatoriske-tilpasninger/https://medwatch.dk/brancher/Medicinal___Biotek/article19191138.ece Updates will certainly follow in the coming days. It is good that NN informs gradually, so fleet possible investors are informed. The news in question began to circulate last week, i.e. the delay is ~1-2 weeks' time in this case, which is fine.
- ·19 t sittenIs it permissible to hope that we are now beginning, after such a long time, to see that the bottom is near. Such a large company should recover at some point, one would think, but this fall has been heavy, especially for those who have their pensions invested there.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 623 | - | - | ||
| 42 | - | - | ||
| 8 695 | - | - | ||
| 2 483 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
2025 Q4 -tulosraportti
66 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
7,95 DKK/osake
Viimeisin osinko
4,86%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·12 t sitten · MuokattuOn 4 February, Danske bank lowered Novo's price target, from 440 to 390 kr. https://www.sydinvest.dk/nyheder/novo-danske-bank-saenker-kursmaal-til-390-kr-fra-440-kr I read 1-2 weeks ago that if DB's price target for Novo were to hold, Novo would need 210,000 weekly prescriptions for the Wegovy pill by the end of the year. My calculation approx. 4,000 per week on average, or 52,000 in week 13, where we were at 77,903. (The last figures we have received) Novo is on its way to raising the lower end of the announced results. UBS price target 332 kr. https://www.nordnet.dk/markedet/nyheder/8dca6395-e9f1-4e52-b677-de3c93956e19 Novo has previously been a "safe haven", but has taken a lot of beating over the last 1.5 years due to disappointing results, so even though there have been several good news recently, it has not risen on them. Most recently yesterday, that Novo can transport their product under more lenient requirements (temperatures in number of hours). When we soon see Eli Lilly's sales figures, we must remember that when Novo entered the market with their pill, it was new. Now this new pill product has been "discussed" for and against for 3 months, before Eli Lilly entered the market, so it might mean that they start with higher sales figures than Novo did. But it will be exciting to follow their figures, versus Novo's. I still believe in Novo and on 6 May, when the figures are presented and future expectations/plans are revealed, I believe that they/we will be rewarded in the share price. Management often gets criticized for this and that, and it's easy to sit and write that they are incompetent and should be replaced. People are frustrated that their "safe" investment, which was supposed to make them millionaires in a week, is suddenly in the red. It's certainly not one's own fault, but Novo management!!! Clearly... I am sure that they work extremely hard every single day to deliver results for us and a lot goes on behind the scenes that we have no idea about. But it's so easy to blame others...
- 18 t sitten18 t sittenInvesting in Novo Feels like having dead money
- ·19 t sitten · MuokattuRead along here: https://finans.dk/erhverv/ECE19188477/novo-nordisk-sammenlaegger-to-afdelinger-og-foretager-organisatoriske-tilpasninger/https://medwatch.dk/brancher/Medicinal___Biotek/article19191138.ece Updates will certainly follow in the coming days. It is good that NN informs gradually, so fleet possible investors are informed. The news in question began to circulate last week, i.e. the delay is ~1-2 weeks' time in this case, which is fine.
- ·19 t sittenIs it permissible to hope that we are now beginning, after such a long time, to see that the bottom is near. Such a large company should recover at some point, one would think, but this fall has been heavy, especially for those who have their pensions invested there.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 623 | - | - | ||
| 42 | - | - | ||
| 8 695 | - | - | ||
| 2 483 | - | - |
Välittäjätilasto
Dataa ei löytynyt